Nanomedicines represent an emerging and new frontier in the development of highly efficacious but potentially less toxic drug treatments through the medium of what is now known as drug delivery systems in the nanoscale. These medicines can deliver in a targeted fashion, have the capability to address the problems of drug resistance as well as deliver multiple molecules simultaneous or sequentially in a time-release fashion. This has revolutionized the concept of pharmaceutics and a considerable amount of research and development is now devoted to new problems of translation that can address such capabilities and also consider new toxicological issues.
Thematic Keynote Overview(15 min)
Dr. Manzoor Koyakutty, Professor, Amrita Centre for Nanosciences and Molecular Medicine
A brief overview of the translational potential and challenges in the area of nanomedicine and how the field has progressed over the last two decade in terms of developing novel therapeutics, their translation and clinical end-use will be discussed.
Bullet Talks(5-7 min each)
- Dr. K. Pavithran, Professor and Head, Medical Oncology, AIMS
Clinical case study 2: Translational issues surrounding the use of Abraxane®, an injectable protein nanomedicine that is indicated for the treatment of breast and lung cancer
- Dr. Dilip Panikar, Professor and Head, Neurosurgery, AIMS
Clinical case study 1: Perspective on the translational issues arising in the use of Gliadel®, a locally implantable wafer in glioblastoma
- Dr. Sahadev Shankarappa, Assistant Professor, ACNS (Formerly, Research Scientist at Prof. Robert Langer’s lab, Massachusetts Institute of Technology, USA)
The problem of dosing in nanomedicine and nano-polypharmaceuticals
- Dr. Y K Gupta, Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
Regulatory aspects of Nanomedicine
- Dr. Suryaprakash Sambhara, Chief, Immunology Section, Influenza Division, CDC, Atlanta, USA
Regulatory issues of vaccine development from the US perspective